Key Takeaways
- Merck’s earnings call on 3 February 2026 at 9:00 a.m. ET will cover Q4 and full-year 2025 sales, earnings, and future outlook, with executives sharing insights on performance.
- Analysts expect Q4 2025 EPS of $2.08 and revenue of $16.2 billion, driven by strong sales from Keytruda and other products, though challenges like supply chains may arise.
- Merck’s 2025 sales are projected to reach $64.5-65 billion, reflecting growth in oncology and vaccines, amid global economic trends like 3.1% growth forecasted by the IMF for 2026.
- Investors should watch for updates on Keytruda, which hit $8.1 billion in Q3 sales, and guidance for 2026, as the pharma sector faces supply issues and declining aid in low-income countries.
- The call could impact Merck’s stock, currently trading around $105, similar to how earnings announcements have influenced peers like Pfizer.
Introduction
Imagine a world where one medicine saves millions of lives while driving billions in revenue for a company. That’s the story of Merck and its blockbuster drug Keytruda, a key player in cancer treatment. As we step into 2026, the pharmaceutical industry is at a crossroads. Global health spending is shifting, with the World Bank noting stagnation in low-income countries and a drop in aid, while the IMF predicts modest economic growth of 3.1% worldwide. In this landscape, Merck, a giant in healthcare, is set to reveal its financial health for 2025.
On 3 February 2026, Merck will hold its fourth-quarter and full-year 2025 sales and earnings conference call. This event isn’t just a routine update; it’s a window into how one of the world’s leading pharma companies navigated a year of challenges and opportunities. From supply chain disruptions to breakthroughs in oncology, the call will offer insights that could shape investor decisions and market trends.
Let’s start with why this matters. Merck, known as MSD outside the US and Canada, has been a cornerstone of healthcare for over 130 years. In 2025, the company faced a mix of headwinds and tailwinds. Global trade tensions, as highlighted in the IMF’s World Economic Outlook, affected supply chains for pharma firms. Yet, Merck’s focus on innovation helped it push forward. Their vaccine and oncology portfolios, especially Keytruda, drove growth despite these issues.
Keytruda, an immunotherapy drug, has been a star performer. In 2025, it crossed new milestones, with Q3 sales alone reaching $8.1 billion – the first time it topped $8 billion in a quarter. This represents a 10% increase from the previous year, showing how early-stage cancer treatments are expanding their market. But with patents set to expire in 2028, investors are keen to hear about what’s next.
The broader economy plays a role too. The Federal Reserve sees rates falling to 3.4% by late 2026, a supportive backdrop for innovation-led firms. Such as Merck. Meanwhile, the World Bank warns of declining donor aid for health in lower-middle-income countries, which could impact global sales of vaccines like Gardasil.
This conference call comes at a pivotal time. Merck’s stock has had a volatile 2025, dropping about 5% overall but recovering from a 17% dip earlier in the year. Trading around $105 in early 2026, shares are below the 52-week high of $112.90. Analysts see growth potential, with a B Growth Style Score and expected 17.4% earnings rise.
What can we expect? Company executives will discuss sales figures, earnings per share, and guidance for 2026. In past calls, topics like tariff impacts and pipeline updates have been hot. For instance, in Q3 2025, Merck reported $17.3 billion in revenue, up 4%, with adjusted earnings of $2.58 per share.
To understand the excitement, think about the pharma industry’s evolution. Post-COVID, focus shifted to oncology and vaccines. Merck’s animal health division also contributed, adding diversity. The IMF notes that regulatory reforms could amplify industrial policies, benefiting firms investing in education and infrastructure – areas where Merck excels.
Investors, from individual shareholders to institutional funds, tune in for clues on dividends, buybacks, and acquisitions. Merck’s recent moves, like acquiring Cidara Therapeutics in January 2026, show a commitment to growth. The call might touch on how this fits into their strategy.
